Given the ever-growing need for more selective, more specific and more affordable imaging biomarkers for recurrent GBM diagnosis and secondary treatment planning, we sought to investigate the role of [68Ga]Ga-PSMA-617 in the management of recurrent GBM patients. Here, FOLH1 is linked to glioblastoma.